SG
IMUX icon

Societe Generale’s Immunic IMUX Stock Holding History

Societe Generale’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$76K Buy
+31
New +$102K ﹤0.01% 2426

Other funds holding IMUX

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Societe Generale's IMUX Position: Q2 2016 in Review

Societe Generale opened a new position in Immunic (IMUX) in Q2 2016: 31 shares worth $76K. The stake represents ﹤0.01% of the portfolio and ranks #2426 among its holdings.

54 funds tracked by Wall St. Rank hold IMUX as of Q2 2016.

  • Societe Generale held 31 shares of Immunic worth $76K as of Q2 2016.
  • Immunic was a new Societe Generale position in Q2 2016.
  • Immunic made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2426 holding.
  • 54 funds tracked by Wall St. Rank held Immunic as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.